OINDPnews

Zeteo Biomedical launches CygnusMR and Cygnus SDX dry powder nasal delivery devices

Texas-based Zeteo Biomedical has announced the launch of two new devices for intranasal delivery of dry powders: the CygnusMR multi-dose device and the CygnusSDX single dose disposable device. In 2022, the company announced the launch of its ZEOx1 OrionMRQ multi-dose nasal device for delivery of … [Read More...] about Zeteo Biomedical launches CygnusMR and Cygnus SDX dry powder nasal delivery devices

Kyorin gets option to license Cyrano’s CYR-064 intranasal theophylline for the Japanese market

Kyorin Pharmaceutical is paying an undisclosed fee for the option to license Japanese development and marketing rights to Cyrano Therapeutics' CYR intranasal theophylline for the treatment of loss of smell, the companies said. A Phase 2 trial of the nasal spray in patients with post-viral … [Read More...] about Kyorin gets option to license Cyrano’s CYR-064 intranasal theophylline for the Japanese market

Kexing Biopharm announces FDA approval of IND for GB05 human interferon α1b inhalation solution

According to Kexing Biopharm, the FDA has approved the company's IND for GB05 human interferon alpha-1b inhalation solution, which the company's subsidiary Shenzhen Kexing plans to advance into clinical development for the treatment of lung infections caused by respiratory syncytial virus in … [Read More...] about Kexing Biopharm announces FDA approval of IND for GB05 human interferon α1b inhalation solution

Ethris gets $5 million from CEPI for development of spray-dried RNA vaccines for nasal delivery

The Coalition for Epidemic Preparedness Innovations (CEPI) is providing $5 million to inhaled RNA developer Ethris for development of spray-dried RNA vaccines for nasal delivery. Ethris said that it plans to focus initially on a vaccine against influenza once a successful process is established. … [Read More...] about Ethris gets $5 million from CEPI for development of spray-dried RNA vaccines for nasal delivery

AIM ImmunoTech announces planned trial of intranasal Ampligen in combination with FluMist against avian flu

AIM ImmunoTech has announced that it plans to move forward with a trial of intranasal Ampligen rintatolimod as an adjuvant to AstraZeneca's FluMist intranasal flu vaccine for the prevention of avian flu. The company said that it plans to run the trial as a follow-up to a 2012 trial of Ampligen in … [Read More...] about AIM ImmunoTech announces planned trial of intranasal Ampligen in combination with FluMist against avian flu

More news . . .